Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia (Q42933358)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 August 2010

Language	Label	Description	Also known as
English	Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia	scientific article published on 19 August 2010

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

11 November 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Naoto Takahashi

1

1 reference

Europe PubMed Central

11 November 2017

Masatomo Miura

2

1 reference

Europe PubMed Central

11 November 2017

Stuart A Scott

3

1 reference

Europe PubMed Central

11 November 2017

Hideaki Kagaya

4

1 reference

Europe PubMed Central

11 November 2017

Yoshihiro Kameoka

5

1 reference

Europe PubMed Central

11 November 2017

Hiroyuki Tagawa

6

1 reference

Europe PubMed Central

11 November 2017

Hirobumi Saitoh

7

1 reference

Europe PubMed Central

11 November 2017

Naohito Fujishima

8

1 reference

Europe PubMed Central

11 November 2017

Tomoko Yoshioka

9

1 reference

Europe PubMed Central

11 November 2017

Makoto Hirokawa

10

1 reference

Europe PubMed Central

11 November 2017

Kenichi Sawada

11

1 reference

Europe PubMed Central

11 November 2017

publication date

19 August 2010

1 reference

Europe PubMed Central

11 November 2017

Journal of Human Genetics

1 reference

Europe PubMed Central

11 November 2017

55

1 reference

Europe PubMed Central

11 November 2017

11

1 reference

Europe PubMed Central

11 November 2017

731-737

1 reference

Europe PubMed Central

11 November 2017

https://scigraph.springernature.com/pub.10.1038/jhg.2010.98

0 references

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Clinical pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Role of organic cation transporters in drug absorption and elimination

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Interaction of imatinib with human organic ion carriers

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Metabolism and disposition of imatinib mesylate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Intestinal drug transporter expression and the impact of grapefruit juice in humans

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Single nucleotide polymorphisms modify the transporter activity of ABCG2.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

21 January 2018

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

The genetic determinants of the CYP3A5 polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Cloning and functional expression of a human liver organic cation transporter

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1)

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2010.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/JHG.2010.98

1 reference

Europe PubMed Central

11 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42933358&oldid=1974035990"